Oncology Drug Approval - Accelerated

Bridging the gap between biomarkers and In Vitro Companion Diagnostics


The MAX Foundation (MAX) is a 501(c)3 US-based organization dedicated to improving the lives of people with blood cancer and rare cancers worldwide. With a focus on Emerging Countries and underserved populations, the organization implements initiatives related to access to treatment as well as treatment monitoring, patient and physician education, and advocacy.  Each year, The MAX Foundation provides free services to over 30,000 families in more than 100 countries, and supports patient associations in 33 countries. Our team of advocates assists with access to treatment, building patient support associations, facilitating educational workshops, and improving access to diagnostics around the world.  




The mission of the iCMLf is to improve outcomes for people with chronic myeloid Leukemia (CML) globally. Formed in 2009 by a leading group of hematologists, the aims of the iCMLf are to foster and coordinate global clinical and research collaborations and to improve CML clinical practice and disease monitoring worldwide.  There are numerous activities that come within the iCMLf’s broad charter but the initial focus of the Foundation is to address the needs in CML that are not already being met by other groups, particularly those needs that are best met by a global organisation. Even in a disease area with effective treatment, so much still needs to be tackled to make sure that all patients around the world receive the best possible therapy and care.   The first priority of the iCMLf was to establish support programs for clinicians working in the developing regions who may not have easy access to appropriate CML diagnostics and monitoring, who are likely to face difficulties in their efforts to update their knowledge and skills regarding best practice for CML patients.  The Emerging Regions Support and Partnership Program is designed to establish supportive one-to-one relationships between key centres of excellence and clinicians in developing regions who have a significant commitment to CML patients. The ERSAP program is regarded as the highest priority and will remain the iCMLf’s major focus of activity over the first few years. The iCMLf thank MolecularMD for their ongoing support for this program.

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes